A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Summary

The trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial in normal weight and overweight but otherwise healthy subjects randomised to subcutaneous administration of ZP8396 or placebo

Timeline

Start

2022-11-07

Primary completion

2024-06-13

Completion

2024-06-13

Outcome

Met primary endpoint

release “Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396” zealandpharma.com ↗

release “Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide” zealandpharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Petrelintide	Protein / enzyme biologic	—	Subcutaneous

Indications